impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Brief Papers

 

Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.

1, 2, 3, 4, 5, 6, 7, 8

 

  1. Dermatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  2. Dermatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  3. Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  4. Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  5. Dermatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  6. Dermatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  7. Dermatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  8. Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy. rscarpa@unina.it

CER9281
2017 Vol.35, N°1
PI 0137, PF 0140
Brief Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27749221 [PubMed]

Received: 22/01/2016
Accepted : 08/04/2016
In Press: 08/09/2016
Published: 26/01/2017

Abstract

OBJECTIVES:
To evaluate the incidence of new cases of psoriatic arthritis (PsA) in patients with plaque psoriasis receiving biologic drugs.
METHODS:
A retrospective study was performed on 434 psoriatic patients under biologic treatment, attending the Psoriasis Care Centre of Dermatology at the University Federico II of Naples from January 2011 to November 2015. As part of the routine clinical practice, assessment of disease activity was made at baseline, and every 3 months. PsA diagnosis was performed by a rheumatologist through clinical examination, evaluation of the CASPAR criteria, laboratory and radiological assessment.
RESULTS:
On the basis of the inclusion and exclusion criteria, we reviewed and analysed the clinical data of 327 patients with plaque psoriasis. The biologic drugs adalimumab, etanercept, infliximab and ustekinumab were prescribed to 116 (35.5%), 88 (27.0%), 27 (8.2%), and 96 (29.3%), respectively. We found that 22 out of 327 patients with plaque psoriasis developed PsA during treatment with biologic drugs. In particular, 6 (27.2%) PsA patients were under etanercept therapy, 10 (45.4%) under adalimumab, 4 (18.2%) under ustekinumab and 2 (9.2%) under infliximab.
CONCLUSIONS:
The results of this study show that in several psoriasis patients, biologic therapy may not be sufficient to prevent the onset of articular involvement. In most of the verified PsA cases, arthritis occurred in concomitance with severe cutaneous involvement.

Rheumatology Article